Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
DataMeds AI, Inc.
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
November 13, 2026
DataMEDS AI Announces Corexa Pharmacy’s First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
November 9, 2026
DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
November 5, 2026
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
November 3, 2026
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
November 2, 2026
DataMEDS AI Establishes “Health Lives Here” Community Respiratory Program for Corexa Health Pharmacy Network
October 23, 2026
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
October 22, 2026
DataMeds Regains Compliance With NASDAQ Listing Standards
October 20, 2026
DataMeds Applauds FDA’s Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health’s Peptides Roadmap
October 16, 2026
DataMEDS Si Licenses U.S. Rights To Reboot Health AI’s Direct-To-Consumer GLP-1 Weight Management Platform
October 14, 2026
1
2
3
4
Next Page
→